本帖最后由 老马 于 2013-3-13 13:43 编辑 ! U( [7 Q% x( J: i" \
^6 f9 x, f9 q# D
健择(吉西他滨)+顺铂+阿瓦斯汀' B6 I- Q5 w3 _2 d7 M
Gemzar +Cisplatin + Avastin# M. ?4 i4 R. k+ a& S' h- z
http://annonc.oxfordjournals.org/content/21/9/1804.full4 y9 j# d: D+ v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 B' G0 ^ T6 c, }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 y* H# C9 y' ?: b1 b/ |! VResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 @& u* _* D3 g5 U1 w; E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 960)
6 ]8 }! Z" W. s- Z9 U: S( D: W华为网盘附件:
3 `) u8 v/ r/ E& J' X' d/ F1 C; K【华为网盘】ava.JPG# ?) f& w4 |. g4 i
|